登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Nucleocapsid protein >NUN-CH15

Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) (MALS verified)

抗体来源(Source)

Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 is a chimeric monoclonal antibody recombinantly expressed from CHO cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Nucleocapsid Protein. This chimeric antibody is purified by Protein A affinity chromatography. As verified by binding test with N-NTD (Cat. No. NUN-C5143) and N-CTD (Cat. No. NUN-C5145) protein, this antibody can only bind to N-CTD (AA Ser 255 - Pro 364). It can also bind multiple N protein variants with similar affinity as compared to the wild type N protein (Cat. No. NUN-C5227).

亚型(Isotype)

Human IgG1/kappa

特异性(Specificity)

This product can recognize SARS-CoV-2 Nucleocapsid protein. Cross-reactivity with Nucleocapsid protein of other coronaviruses has not been tested.

应用(Application)

This antibody can be paired with other Anti-SARS-CoV-2 nucleocapsid antibodies (Cat. No. NUN-CH14) to detect SARS-CoV-2 nucleocapsid protein in sandwich ELISA or LFA assay.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

制剂(Formulation)

Supplied as 0.2 μm filtered solution in PBS, pH7.4.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
  2. For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt.
 

电泳(SDS-PAGE)

Nucleocapsid protein SDS-PAGE

Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

Nucleocapsid protein SEC-MALS

The purity of Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) (Cat. No. NUN-CH15) is more than 95% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Nucleocapsid protein ELISA

Immobilized SARS-CoV-2 (COVID-19) Nucleocapsid protein, His Tag (Cat. No. NUN-C5227) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AM223) (Cat. No. NUN-CH15) with a linear range of 0.2-6 ng/mL (Routinely tested).

Protocol

Nucleocapsid protein ELISA

Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AM223) (Cat. No. NUN-CH15) at 1μg/mL (100μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (B.1.1.529/Omicron) (Cat. No. NUN-C52Ht) with a linear range of 0.2-6 ng/mL (Routinely tested).

Protocol

 

背景(Background)

Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Nucleocapsid protein靶点信息
英文全称:Nucleocapsid proteins
中文全称:核壳蛋白
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:1详情
最高研发阶段:临床一期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定